Related Experiment Video

Updated: Nov 23, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.7K

Cutaneous reactions to pediatric cancer treatment part II: Targeted therapy

Valerie M Carlberg1,2, Olivia M T Davies2, Heather A Brandling-Bennett3,4

  • 1Children's Wisconsin, Milwaukee, WI, USA.

Pediatric Dermatology
|December 30, 2020
PubMed

Insights

Pediatric cancer patients experience common skin, hair, and nail side effects from targeted therapies. Understanding these dermatologic adverse events (AEs) is crucial for managing treatment and improving quality of life.

Area of Science:

  • Pediatric Oncology
  • Dermatology
  • Pharmacology

Background:

  • Cancer is a major cause of childhood illness and death.
  • Targeted therapies offer improved survival but present unique side effects.
  • Dermatologic adverse events (AEs) are common but poorly described in children.

Purpose of the Study:

  • To characterize dermatologic AEs in pediatric patients receiving targeted anticancer therapies.
  • To summarize clinical findings and provide treatment recommendations for pediatric dermatologic AEs.
  • To highlight the need for better documentation of these AEs in pediatric oncology literature.

Main Methods:

  • Literature review of dermatologic AEs associated with targeted anticancer therapies.
  • Analysis of available data on clinical manifestations and treatment strategies.
  • Focus on therapies available up to July 2020.

Main Results:

  • Dermatologic AEs are frequent in children undergoing targeted cancer therapy.
  • Morphologic and histologic descriptions of these AEs are often lacking in published studies.
  • Pediatric dermatologists can identify specific AEs and guide management.

Conclusions:

  • Dermatologic AEs significantly impact pediatric cancer patients' quality of life and treatment adherence.
  • Standardized reporting and understanding of pediatric dermatologic AEs are needed.
  • Expertise from pediatric dermatologists is vital for optimizing care and enabling continued cancer therapy.
Keywords:
adverse reactionscutaneous toxicityoncodermatologypediatrictargeted therapy

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.3K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.6K

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
877
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
4.9K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
90